News Owlstone's breath diagnostic to be used in asthma research Owlstone's ReCIVA and FAIMS technologies will be used to discover asthma-specific biomarkers.
News Owlstone's breath-based lung cancer diagnostic could save 10... Trial's next phase will recruit 3,000 patients across 21 international sites.
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
